DIPROLENE AF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIPROLENE AF (DIPROLENE AF).
Betamethasone dipropionate is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, thereby reducing the release of arachidonic acid and subsequent production of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Primarily hepatic via CYP3A4; undergoes glucuronidation and sulfation. |
| Excretion | Primarily hepatic metabolism; inactive metabolites excreted renally (approximately 80-85% as metabolites in urine) and fecally (approximately 15-20%). |
| Half-life | Approximately 2.5-3 hours (terminal half-life) for betamethasone dipropionate (active moiety); clinical effects persist beyond half-life due to receptor-mediated activity. |
| Protein binding | Approximately 64-70% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Not well characterized for topical formulation; systemic Vd for betamethasone is approximately 0.6-1.4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: Systemic absorption is low (approximately 7-15% of applied dose) through intact skin; absorption increases with occlusive dressings, inflamed skin, or prolonged use. |
| Onset of Action | Topical: 2-3 days for measurable clinical improvement in inflammatory dermatoses. |
| Duration of Action | Topical: Once-daily application maintains effect for 24 hours; clinical improvement sustained with continued use. |
Apply a thin film to affected skin areas twice daily. Maximum 45 g per week. Not to exceed 2 consecutive weeks of treatment.
| Dosage form | CREAM, AUGMENTED |
| Renal impairment | No dosage adjustment required for renal impairment. Systemic absorption is minimal when used topically. |
| Liver impairment | No specific recommendations for hepatic impairment. Caution in severe hepatic impairment due to potential for increased systemic absorption. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. Use not recommended in children under 12 years of age due to higher skin surface-to-body weight ratio increasing risk of systemic adverse effects. For children 12 years and older, follow adult dosing with caution, limited to shortest duration possible. |
| Geriatric use | Use with caution in elderly patients due to age-related skin thinning and potential for increased systemic absorption. Limit duration and area of application to minimize risk of local and systemic adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DIPROLENE AF (DIPROLENE AF).
| Breastfeeding | Minimal systemic absorption after topical application; betamethasone is excreted into breast milk in negligible amounts. M/P ratio not determined. No expected adverse effects in breastfed infant with maternal topical use, but avoid application to breast to prevent infant ingestion. Caution with prolonged or high-dose use. |
| Teratogenic Risk | Corticosteroids cross the placenta. First trimester: Increased risk of cleft palate (odds ratio 3.4) based on observational studies. Second/third trimester: Risk of fetal adrenal suppression, low birth weight, and preterm birth with prolonged high-dose systemic use. Topical application (including augmented betamethasone) has minimal systemic absorption; however, large areas, occlusion, or broken skin may increase risk. Avoid high-potency steroids on face, flexures, or during pregnancy unless necessary. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to betamethasone dipropionate or any component of the formulation, untreated bacterial, fungal, viral, or parasitic skin infections
| Precautions | Reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, skin atrophy, striae, telangiectasias, potential for systemic effects if applied to large body surface areas or occlusive dressings, exacerbation of infections, delayed wound healing, perioral dermatitis, allergic contact dermatitis, posterior subcapsular cataracts, glaucoma. |
Loading safety data…
| Fetal Monitoring | Monitor for maternal skin atrophy, striae, or infection at application site. In prolonged high-dose use or large body surface area applications, consider periodic assessment of maternal blood pressure, blood glucose, and growth ultrasound for fetal growth restriction. No routine drug level monitoring required. |
| Fertility Effects | No specific studies on Diprolene AF and fertility. Systemic corticosteroids may cause menstrual irregularities or ovulatory dysfunction at high doses. Topical application with minimal systemic absorption is unlikely to impair fertility. No evidence of adverse effects on spermatogenesis from topical use. |